TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: MSD Influenza B Test Results Against Cell Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MSD Influenza A Test Results Against Culture and PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MSD Influenza B Test Results Against Culture and PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency of stroke and TIA mimics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Alive and Ventilator Free Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited symptoms after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited symptoms after each vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse events during the study period
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Growth Rate as Measured by PSA Rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ACR 20% improvement criteria (ACR20) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR50 & ACR70 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity scale in 28 joints (DAS-28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometry of the visceral and renal branches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Manual lymphatic vessel counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphatic contraction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICG clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with breast softness and natural appearance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative recovery speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in substance use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of other STIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Chemotherapy tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Dose reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3-5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Response to treatment according to RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Palbociclib in Stratum I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Palbociclib in Stratum II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Pain Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impacts on organizational processes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Flow Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in flow velocity integral (FVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of TLR-MACE
Endpoint domain: Mortality/survival
Primary endpoint: Need for additional anti-VEGF treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Diurnal Intraocular Pressure (MDIOP) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters (AUC, CMAX, TMax, t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 24-hour Mean Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial plasma glucose at 60 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IIEF-ED Domain
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Risk for a specific adverse condition
Endpoint domain: Adverse events/effects
Primary endpoint: Parathyroid function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: bucco lingual and crestal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Microglial Activation Reserve Index (MARI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PANSS-EC Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure Freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quality of Life documentation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Shoulder Pain and Disability Index (SPADI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Grade 2 and Above Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants diagnosed with epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: compression ratio change of anterior border of vertebral body height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Depth of nail into injured vertebrae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Kyphosis (Cobb) angle change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Phenylalanine kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tyrosine kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Palmitate balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration versus time curves (AUC0 - 72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HHS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tacrolimus intra-PBMC concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peptide specific immunologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Regulatory T cells (Treg) number changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of RA Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of viral RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bad-Outcome Composite Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in preload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking-related Gene Expression Signature Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SRM P31 assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic blood pressure amplification change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GDM detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in myotonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incremental area-under-the-concentration-curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of first hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reason for hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With CRC Screening Ordered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: respiration mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Pain Relief (PR) at 2 Hours Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One or More Adverse Events Within 48 Hours Post-Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Self-efficacy to Quit Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy to Cut Down on Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Extent of Motivation to Quit Smoking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distance penetrated by the Explorer at the tooth restoration interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The degree of mismatch from the normal range of tooth shades and translucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain due to dentin hypersensitivity (evaporative stimulus)
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting Plasma Glucose (FPG) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting Insulin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Glycosylated Hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seizure frequency per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With Best (Overall) Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-18 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oral appliance compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of the motor scale of Burke-Fahn-Marsden-Dystonia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of abdominal adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in vascular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: graded intubation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of PIPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients receiving ≥ 1 PIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hematocrit %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fibrinogen mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: heart stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: brain stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: early reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Physical condition
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Depression patient health questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Back pain limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Roland disability score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC(0-Inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Time Point (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of total phone sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean ease ratings of exercises
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean utility ratings of exercises
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sensitivity and specificity of olfaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper limb kinematic behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIF-1α Protein Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular Access Site Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: change of pocket depths (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of clinical attachment levels (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease free state off anthelmintics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned Re-hospitalization and Emergency/Urgent Care Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reproducibility of NAP signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Discriminant ability of NAP signal in normal or abnormal lung segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of NAFLD in psoriasis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Complication rates after stage I and II
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Cystatin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuity of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ADHD core symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response to influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositive rate of anti-EV71 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositive rate of anti-EBV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositive rate of anti-measles virus antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositive rate of anti-Rubella virus antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate of anti-EV71 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to initiation of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to relapse after discontinuation of IFX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glottis Visualization POGO Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From the Insertion of the Laryngoscope Blade to Confirm w/ CO2 Waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of drug-related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assess immunogenicity of tisotumab vedotin by measuring and assessing Anti-drug Antibody (ADA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of GVHD prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Habitual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in heart rate during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in mean arterial blood pressure during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive Benefits
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of DLTs Observed in Evaluable Patients
Endpoint domain: Adverse events/effects
Primary endpoint: Patients With Buparlisib Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: WOMAC change assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of prostate lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety assessed by frequency of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Disease activity score (DAS28) - C-reactive protein (CRP)
Endpoint domain: Physiological/clinical
Primary endpoint: Percentage of participants achieving DAS28-CRP scores for remission
Endpoint domain: Physiological/clinical
Primary endpoint: Post-procedure hemorrhage rate changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occlusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retreatment rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gastric Retention by Scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: dengue virus genomic RNA detection in patient sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder Rate for Nasolabial Folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder Rate for Marionette Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder Rate for Cheek Fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Attention Bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of disease discrepancies in bone marrow involvement by ALL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of discrepancies in identification of CNS involvement by leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immunophenotypic changes in leukemic cells over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for first request to rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Goldmann applanation tonometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of medication requiring neonatal abstinence syndrome (NAS)
Endpoint domain: Adverse events/effects
Primary endpoint: Y-BOCS score average difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reaching target LDL-C goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Upper limbs functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic response to proton-pump inhibitor (PPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional ability in the everyday context
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Horizontal Intermediate Visual Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal Near Visual Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized Bleeding Episode Rate (ABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC[0-24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes